The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects

We present novel data demonstrating that the expression of PPARγ is reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients. Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from...

Full description

Saved in:
Bibliographic Details
Main Authors: Galina S. Bogatkevich, Kristin B. Highland, Tanjina Akter, Richard M. Silver
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Pulmonary Medicine
Online Access:http://dx.doi.org/10.1155/2012/545172
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items